CRT-402 for autoimmune disease
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This study tests a new treatment, CRT-402, for people with certain autoimmune diseases who have not improved with standard treatments. It aims to find out if this treatment is safe and if it helps control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a diagnosis of systemic lupus erythematosus (SLE), systemic sclerosis, or myositis that is active and has not responded to standard therapy.
- Your liver, kidneys, heart, and lungs must work well enough to participate.
- If you can become pregnant or get someone pregnant, you must agree to use effective birth control during the study and for a time after.
- You must be able to attend study visits and follow the study plan.
- You cannot have had prior treatment with a CD19-targeted therapy, cell therapy (like CAR-T), or gene therapy.
- You cannot have a history of bone marrow, stem cell, or organ transplantation.
- You cannot have an active infection such as HIV, hepatitis B, hepatitis C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.